Literature DB >> 3636325

In-vitro activity of ticarcillin with and without clavulanic acid against clinical isolates of gram-positive and gram-negative bacteria.

G Pulverer, G Peters, G Kunstmann.   

Abstract

The in-vitro activity of ticarcillin with and without clavulanic acid was investigated against 285 freshly isolated clinical strains of Gram-positive and Gram-negative bacteria by the agar-dilution technique on Mueller-Hinton-agar. Clavulanic acid had an excellent or moderate potentiating effect on the in-vitro activity of ticarcillin against staphylococci, Escherichia coli, Klebsiella spp., Enterobacter aerogenes, Proteus mirabilis, Citrobacter spp., Acinetobacter, Haemophilus influenzae and Bacteroides spp. No effect was seen against enterococci, indole-positive Proteus spp., Ent. cloacae, Serratia marcescens and Pseudomonas aeruginosa. The effect of clavulanic acid was dose- and inoculum-dependent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3636325     DOI: 10.1093/jac/17.suppl_c.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  Pharmacokinetics and bacteriological efficacy of ticarcillin-clavulanic acid (timentin) in experimental Escherichia coli K-1 and Haemophilus influenzae type b meningitis.

Authors:  G A Syrogiannopoulos; A Al-Sabbagh; K D Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.